Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPACE-T: tarlatamab in extensive-stage small-cell lung cancer with poor performance status
2025-522437-65-00Phase 2Authorised
- Sponsor
- AIO-Studien
- Start
- Mar 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tarlatamab in small cell lung cancer (SCLC), sponsored by AIO-Studien. Primary endpoint: Overall survival rate at 12 months. Planned start Mar 2026; status: authorised.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2025-522437-65-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522437-65-00.